[1] Lin L, Cheng J, Tang D, et al. The associations among quantitative spectral CT parameters, Ki-67 expression levels and EGFR mutation status in NSCLC[J]. Sci Rep, 2020, 10(1): 3436.
[2] Leonetti A, Assaraf Y G, Veltsista P D, et al. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: current implications and future directions[J]. Drug Resist Updat, 2019, 42(1): 1-11.
[3] Gelatti A C Z, Drilon A, Santini F C. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)[J]. Lung Cancer, 2019, 137(11): 113-122.
[4] Rebuzzi S E, Alfieri R, La Monica S, et al. Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives[J]. Crit Rev Oncol Hematol, 2019, 31(10): 102820.
[5] Sugawara S, Oizumi S, Minato K, et al. Randomized phase Ⅱ study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902[J]. Ann Oncol, 2015, 26(5): 888-894.
[6] Cheng Y, Murakami H, Yang P C, et al. Randomized phase Ⅱ trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations[J]. J Clin Oncol, 2016, 34(27): 258-266.
[7] Miyauchi E, Inoue A, Kobayashi K, et al. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized phase Ⅲ study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)[J]. Int J Clin Oncol, 2015, 45(7): 670-676.
[8] Zhang Y Q, Jiang L J, Jiang S X, et al. Gefitinib with or without transarterial infusion chemotherapy (cisplatin) for large nonsmall cell lung cancer with epidermal growth factor receptor mutations[J]. J Vasc Interv Radiol, 2019, 30(7): 1004-1012.
[9] Jänne P A, Wang X, Socinski M A, et al. Randomized phase Ⅱ trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial[J]. J Clin Oncol, 2012, 30(17): 2063-2069.
[10] Halmos B, Pennell N A, Fu P, et al. Randomized phase ii trial of erlotinib beyond progression in advanced erlotinib responsive non small cell lung cancer[J]. Oncologist, 2015, 20(11): 1298-1303.
[11] Tamiya M, Tamiya A, Shiroyama T, et al. Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations[J]. Invest New Drugs, 2018, 36(4): 608-614.
[12] Takashina T, Asahina H, Oizumi S, et al. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)[J]. Int J Clin Oncol, 2018, 23(6): 1060-1069.
[13] Kelly D, Burke L, O′Brien C, et al. Co-occurrence of EGFR sensitising and resistance mutations at diagnosis in NSCLC[J]. Ir J Med Sci. 2019, 188(2):405-408.
[14] Pan Y, Gao G, Chen X, et al. Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer[J]. Thorac Cancer. 2019, 10(4):686-694.
[15] Li X, Cai W, Yang G, et al. Comprehensive analysis of EGFR mutant abundance and its effect on efficacy of EGFR TKIs in advanced NSCLC with EGFR mutations[J]. J Thorac Oncol, 2017, 12(9): 1388-1397.
[16] Yan X, Wang H, Li P, et al. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation[J]. Lung Cancer, 2019, 128(2): 6-12.
[17] Uchibori K, Satouchi M, Sueoka A N, et al. Phase Ⅱ trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations[J]. Lung Cancer, 2018, 124(10): 65-70.
[18] Ding T, Zhou F, Chen X, et al. Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations[J]. J Thorac Dis, 2017, 9(9): 2923-2934.
[19] O′Brien M E R, Sarker D, Bhosle J, et al. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors[J]. Cancer Chemother Pharmacol, 2018, 82(5): 757-766.
[20] Lee V H F. Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer[J]. Asia Pac J Clin Oncol, 2018, 18(3): 4-6.
[21] Watanabe S, Yamaguchi O U, Masumoto A I, et al. Phase I study evaluating the combination of afatinib with carboplatin and pemetrexed after first-line EGFR-TKIs[J]. Anticancer Res, 2018, 38(8): 4699-4704.
[22] Lin L, Ge H, Yan Z, et al. Response to afatinib in a patient with non-small cell lung cancer harboring HER2 R896G mutation: a case report[J]. Onco Targets Ther, 2019, 12(3): 10897-10902.
[23] Kim C, Liu S V. First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward[J]. Ann Oncol, 2019, 30(12): 1852-1855.
[24] Moeller M, Siebolts U, Wickenhauser C, et al. Non-small cell lung cancer development of parallel mechanisms of resistance[J]. Pneumologie, 2018, 72(7): 503-506.
[25] Hirakawa H, Komiya K, Nakashima C, et al. A case of osimertinib-resistant lung adenocarcinoma responded effectively to alternating therapy[J]. Ann Transl Med, 2018, 6(23): 464.
[26] La M S, Minari R, Cretella D, et al. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC[J]. J Exp Clin Cancer Res, 2019, 38(1): 222.